Royal Bank of Canada
DFTX

Royal Bank of Canada’s Definium Therapeutics DFTX Stock Holding History

Royal Bank of Canada’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.84M Buy
97,192
+3,566
+4% +$60.5K ﹤0.01% 3151
2025
Q4 		$1.25M Buy
93,626
+41,867
+81% +$518K ﹤0.01% 3492
2025
Q3 		$611K Sell
51,759
-45,370
-47% -$423K ﹤0.01% 4331
2025
Q2 		$629K Buy
97,129
+31,892
+49% +$210K ﹤0.01% 4283
2025
Q1 		$382K Buy
65,237
+6,148
+10% +$44K ﹤0.01% 4193
2024
Q4 		$410K Buy
59,089
+2,401
+4% +$16.5K ﹤0.01% 4228
2024
Q3 		$323K Sell
56,688
-10,210
-15% -$71K ﹤0.01% 4442
2024
Q2 		$483K Buy
66,898
+26,279
+65% +$230K ﹤0.01% 4043
2024
Q1 		$381K Buy
40,619
+35,234
+654% +$201K ﹤0.01% 4161
2023
Q4 		$20K Buy
5,385
+939
+21% +$2.83K ﹤0.01% 6312
2023
Q3 		$13K Sell
4,446
-3,028
-41% -$12.4K ﹤0.01% 6338
2023
Q2 		$27K Buy
7,474
+2,824
+61% +$9.74K ﹤0.01% 6059
2023
Q1 		$14K Sell
4,650
-561
-11% -$1.86K ﹤0.01% 6174
2022
Q4 		$11K Sell
5,211
-8,233
-61% -$22.9K ﹤0.01% 6512
2022
Q3 		$47K Buy
13,444
+9,116
+211% +$87.5K ﹤0.01% 5772
2022
Q2 		$41K Sell
4,328
-1,848
-30% -$23.4K ﹤0.01% 5806
2022
Q1 		$103K Sell
6,176
-3,402
-36% -$59K ﹤0.01% 5627
2021
Q4 		$199K Buy
9,578
+3,177
+50% +$101K ﹤0.01% 5338
2021
Q3 		$223K Sell
6,401
-884
-12% -$38.2K ﹤0.01% 5071
2021
Q2 		$377K Buy
+7,285
New +$382K ﹤0.01% 4516

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada's DFTX Position: Q1 2026 in Review

Royal Bank of Canada increased its Definium Therapeutics (DFTX) stake by 3.8% in Q1 2026, buying an estimated $60.5K and bringing the position to 97,192 shares worth $1.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3151.

Royal Bank of Canada first reported a position in DFTX in Q2 2021 and has held it in 20 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Royal Bank of Canada held 97,192 shares of Definium Therapeutics worth $1.84M as of Q1 2026.
  • Royal Bank of Canada bought 3,566 Definium Therapeutics shares in Q1 2026, an estimated $60.5K.
  • Definium Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3151 holding.
  • Royal Bank of Canada first reported a position in Definium Therapeutics in Q2 2021 and has held it in 20 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.